Butterfly Medical Announces First BPH Clinical Study Procedures Performed in North America for its Next Generation Minimally Invasive Solution
First procedures were successfully performed under local anesthesia in an office setting by Steven Gange MD FACS, Summit Urology, Utah.
Butterfly Medical, an Israeli medical device company developing a novel minimally invasive solution to treat Benign Prostatic Hyperplasia (BPH), today announced its first procedures performed in-office under local anesthesia in its clinical study in North America.
The clinical study evaluates the safety and effectiveness of Butterfly’s next generation prostatic retraction device: a proprietary nitinol implant designed to gently open and prevent the blockage from an enlarged prostate for improved urine flow and thereby alleviate the symptoms caused by BPH. It is considered a “next gen” BPH therapy as it is reversible while also not requiring heating, cooling, cutting or piercing of the prostate.
The first North American procedures were successfully performed by Dr. Steven Gange, (Salt Lake City, UT) clinical study Principal Investigator.